The Defense Health Agency awarded the University of Pennsylvania $3.5 million under the Military Medical Research and Development program on November 1, 2026, to develop podocyte-protective therapies for focal segmental glomerulosclerosis (FSGS). The project runs through October 31, 2030, with performance based in Philadelphia, Pennsylvania. The Military Medical Research and Development program (CFDA 12.420) supports basic, applied, and advanced biomedical research to transform health care for service members and the American public through innovative research and investigation of medical solutions for battlefield applications.